Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients
Status:
Suspended
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the influence of celecoxib on relapse-free survival in
completely resected patients with poor prognosis indicated by metastatic involvement of
intrapulmonary/hilar (pN1) or ipsilateral mediastinal (pN2) lymph nodes. Celecoxib, a
selective oral COX-2 inhibitor, was found to exert significant anti-proliferative activity
against a variety of tumor cell lines in vitro, including NSCLC. COX-2 is frequently
up-regulated in NSCLC cell lines and archival tumor samples. Its high expression was also
correlated with poor prognosis of the patients. A clinical trial addressing the role of
celecoxib as adjuvant treatment in radically operated patients with high risk of relapse is
warranted.
Phase:
Phase 3
Details
Lead Sponsor:
Medical University of Gdansk
Collaborators:
Central and Eastern European Oncology Group Pharmacia Stowarzyszenie Ludzi Wyleczonych z Raka Płuca